Schizophrenia (Heidelberg, Germany)最新文献

{"title":"Assessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative study.","authors":"Sebastien Tulliez, Stella Karantzoulis, James C Marcus, Montserrat Casamayor, Cassie Blanchard, Haig Goenjian, Joshua T Kantrowitz, Lara Shirikjian, John Sonnenberg, Corey Reuteman-Fowler, Philip D Harvey, Richard S E Keefe","doi":"10.1038/s41537-025-00619-9","DOIUrl":"https://doi.org/10.1038/s41537-025-00619-9","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is a core feature of schizophrenia, profoundly impacting patients' functional abilities. As such, evaluating cognition-related functional activity/impairment is essential for identifying effective treatments. This study presents findings from a non-interventional quantitative study to assess the inter-rater reliability (IRR) of the Schizophrenia Cognition Rating Scale (SCoRS) with a sample representative of clinical trial populations.</p><p><strong>Methods: </strong>Structured, one-to-one, 10-15-minute live interviews with patients with schizophrenia were conducted by trained SCoRS interviewers (raters), and a separate interview was then conducted with the patient's study partner (informant). Both interviews were recorded so that each interview was assessed by three different SCoRS raters in total (one live, two via recording). IRR was assessed using interclass correlation (ICC) and categorized as low (<0.70), good (0.70-0.90), or excellent (>0.90).</p><p><strong>Results: </strong>A total of 44 patients with schizophrenia were evaluated by 12 raters (overall). The SCoRS Total Score (mean [SD]: 41.4 [10.2]) indicated moderate-to-moderately-severe impairment of cognition-related functioning, with high inter-patient variability. The SCoRS Total Score demonstrated excellent IRR, with an ICC of 0.91 (95% CI 0.88-0.95).</p><p><strong>Conclusion: </strong>The 20-item SCoRS Total Score demonstrated excellent IRR in assessing cognition-related functional capacity in patients with schizophrenia, supporting its use as an endpoint in clinical studies.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"71"},"PeriodicalIF":3.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of morphometric similarity networks in health and schizophrenia.","authors":"Joost Janssen, Ana Guil Gallego, Covadonga Martínez Díaz-Caneja, Noemi Gonzalez Lois, Niels Janssen, Javier González-Peñas, Pedro Macias Gordaliza, Elizabeth Buimer, Neeltje van Haren, Celso Arango, René Kahn, Hilleke E Hulshoff Pol, Hugo G Schnack","doi":"10.1038/s41537-025-00612-2","DOIUrl":"https://doi.org/10.1038/s41537-025-00612-2","url":null,"abstract":"<p><p>Reduced structural network connectivity is proposed as a biomarker for chronic schizophrenia. This study assessed regional morphometric similarity as an indicator of cortical inter-regional connectivity, employing longitudinal normative modeling to evaluate whether decreases are consistent across individuals with schizophrenia. Normative models were trained and validated using data from healthy controls (n = 4310). Individual deviations from these norms were measured at baseline and follow-up, and categorized as infra-normal, normal, or supra-normal. Additionally, we assessed the change over time in the total number of infra- or supra-normal regions for each individual. At baseline, patients exhibited reduced morphometric similarity within the default mode network compared to healthy controls. The proportion of patients with infra- or supra-normal values in any region at both baseline and follow-up was low (<6%) and similar to that of healthy controls. Mean intra-group changes in the number of infra- or supra-normal regions over time were minimal (<1) for both the schizophrenia and control groups, with no significant differences observed between them. Normative modeling with multiple timepoints enables the identification of patients with significant static decreases and dynamic changes of morphometric similarity over time and provides further insight into the pervasiveness of morphometric similarity abnormalities across individuals with chronic schizophrenia.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"70"},"PeriodicalIF":3.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia.","authors":"Chao Li, Chuanjun Zhuo, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang, Hongjun Tian, Lina Wang","doi":"10.1038/s41537-025-00618-w","DOIUrl":"https://doi.org/10.1038/s41537-025-00618-w","url":null,"abstract":"<p><p>In 2017, the Food and Drug Administration (FDA) approved valbenazine and deutetrabenazine, two vesicular monoamine transporter 2 (VMAT2) inhibitors, as treatments for tardive dyskinesia (TD). Additionally, some trials have suggested that vitamin E may benefit TD patients. However, the mechanistic basis for these treatments remains unclear. The objective of this study was to analyze and compare the mechanisms of valbenazine, deutetrabenazine, and vitamin E in TD treatment utilizing network pharmacology and molecular docking approaches. Putative target genes associated with valbenazine, deutetrabenazine, and vitamin E were retrieved from the PharmMapper, CTD, GeneCards, SwissTargetPrediction, and DrugBank databases. TD-related targets were identified using the GeneCards, DisGeNET, OMIM, and TTD databases. A protein-protein interaction (PPI) network was created to identify core targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted via DAVID, and Cytoscape was used to build a drug-pathway-target-disease network. Molecular docking evaluated drug-target interactions. A total of 32, 36, and 62 targets relevant to the treatment of TD were identified for valbenazine, deutetrabenazine, and vitamin E, respectively. PPI and KEGG pathway analyses suggested that valbenazine and deutetrabenazine may influence TD through the dopaminergic synapse signaling pathway via common core targets (e.g., Dopamine Receptor D1 (DRD1), DRD2, Monoamine Oxidase B (MAOB), Solute Carrier Family 6 Member 3 (SLC6A3), SLC18A2) and specific targets (DRD3 for valbenazine, MAOA for deutetrabenazine). Vitamin E may affect TD by targeting the PI3K-Akt pathway through AKT Serine/Threonine Kinase 1 (AKT1), Brain-Derived Neurotrophic Factor (BDNF), Insulin (INS), Nitric Oxide Synthase 3 (NOS3), and Toll-Like Receptor 4 (TLR4). This study provides insights into the common and unique molecular mechanisms by which valbenazine, deutetrabenazine, and vitamin E may treat TD. Pharmacological experiments should be conducted to verify and further explore these results. The findings offer a theoretical basis for further pharmacological investigation and a resource for TD drug screening.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"69"},"PeriodicalIF":3.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aberrant aging-associated p62 autophagic cascade in biopsied olfactory neuronal cells from patients with psychosis.","authors":"Kun Yang, Koko Ishizuka, Toshifumi Tomoda, Akira Sawa","doi":"10.1038/s41537-025-00617-x","DOIUrl":"https://doi.org/10.1038/s41537-025-00617-x","url":null,"abstract":"<p><p>Sequestosome-1/p62, a key mediator in the clearance of damaged organelles and macromolecules during autophagy, serves as a marker of biological aging. We demonstrate elevated p62 in biopsied neuronal cells in patients with psychosis compared to healthy controls. In healthy controls, p62-indicated biological/autophagic age is positively correlated with chronological age over time, whereas in patients, neuronal p62-indicated biological/autophagic age shows no correlation with chronological age, being significantly higher than chronological age from the onset of the disease.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"68"},"PeriodicalIF":3.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of real-world driving behavior in people with schizophrenia: a naturalistic study utilizing drive recorders.","authors":"Hiroki Okada, Saki Komagata, Mayu Takagi, Yuichi Kamata, Junichi Matsumoto, Takaya Maeyama, Yukiko Takashio, Masaki Matoba","doi":"10.1038/s41537-025-00613-1","DOIUrl":"https://doi.org/10.1038/s41537-025-00613-1","url":null,"abstract":"<p><p>Research on driving among people with schizophrenia (PWS) is limited to laboratory-based studies. The present study aimed to compare PWS with healthy controls (HC) in real-world driving behaviors using 500 km of driving data collected through dashcams. Neuropsychological tests were conducted to evaluate both PWS and HC. After the evaluation, we compared traffic violations with dangerous driving behaviors, such as sudden braking and abrupt steering. PWS were treated with antipsychotics and antiparkinsonians and were evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Drug-Induced Extrapyramidal Symptoms Scale. Statistical analysis included factor analysis, which was employed to evaluate the classification of violations and driving behaviors; correlation coefficients were employed to evaluate actual driving behavior. The results indicated that the mean driving speed was significantly lower, instances of speeding were absent, and the frequency of inhibition-related driving violations, such as smartphone use while driving, was lower. Violations related to inattention were associated with sustained attention and the useful field of view (UFOV). These findings suggest that PWS are less likely to engage in reckless driving compared to HC. Furthermore, considering that driving violations among PWS may be attributed to cognitive errors, the results highlight the importance of assessing and addressing cognitive functions in driver assistance systems to promote safer driving. One limitation of the study was that the severity of psychopathology among the participants was relatively low, which may have contributed to the PANSS, its subscales, and factors being less predictive of traffic violations.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"67"},"PeriodicalIF":3.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal eye movement, brain regional homogeneity in schizophrenia and clinical high-risk individuals and their associated gene expression profiles.","authors":"Zhaobin Chen, Yangpan Ou, Yudan Ding, Ying Wang, Huabing Li, Feng Liu, Ping Li, Dongsheng Lv, Yong Liu, Bing Lang, Jingping Zhao, Wenbin Guo","doi":"10.1038/s41537-025-00609-x","DOIUrl":"https://doi.org/10.1038/s41537-025-00609-x","url":null,"abstract":"<p><p>Clinical high-risk (CHR) is a prodromal period before psychosis characterized by attenuated, transient, or intermittent psychotic symptoms and declining functioning. They exhibit eye movement abnormalities and brain functional damage compared with schizophrenia, potentially increasing vulnerability to psychosis. This study investigates eye movement dysfunction and brain activity alterations in CHR and first-episode schizophrenia (FSZ) individuals to identify early biomarkers for psychosis progression. Twenty-seven drug-naïve FSZ, 25 CHR, and 28 healthy controls (HCs) were recruited for eye-tracking tasks and resting-state functional magnetic resonance imaging to evaluate eye movement and regional homogeneity (ReHo) differences. Machine-learning algorithms were used to differentiate FSZ from CHR. In combination with the Allen Human Brain Atlas (AHBA), transcriptome-neuroimaging analysis was applied to identify ReHo-related gene expression profiles. FSZ exhibited a wide range of eye movement abnormalities across multiple tasks, while certain abnormalities were already present in CHR. Abnormal ReHo alterations were found in orbitofrontal gyrus, temporal gyrus, and cingulum among three groups, associated with specific eye movement parameters. These differences in eye movement and ReHo allowed for high-accuracy discrimination between them. Genetic analysis identified significant genes in FSZ and CHR, enriched in various biological functions and pathways (all corrected p < 0.05). FSZ and CHR exhibited different eye movement and ReHo patterns, indicating potential as early biomarkers. Our findings reveal correlations between these ReHo patterns and gene expression profiles using AHBA database, shedding light on possible genetic mechanisms underlying brain function in FSZ and CHR.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"64"},"PeriodicalIF":3.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.","authors":"Stefania Tognin, Sandra Vieira, Dominic Oliver, Alexis E Cullen, Mathew J Kempton, Paolo Fusar-Poli, Andrea Mechelli, Paola Dazzan, Kate Merritt, Arija Maat, Lieuwe de Haan, Stephen M Lawrie, Thérèse van Amelsvoort, Celso Arango, Barnaby Nelson, Silvana Galderisi, Rodrigo Bressan, Jun Soo Kwon, Romina Mizrahi, Rene S Kahn, Philip McGuire","doi":"10.1038/s41537-025-00598-x","DOIUrl":"https://doi.org/10.1038/s41537-025-00598-x","url":null,"abstract":"<p><p>Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The PSYSCAN project aimed to enhance predictive value by integrating data across clinical, environmental, neuroimaging, cognitive, and peripheral blood biomarkers. PSYSCAN employed a naturalistic, prospective design across 12 sites (Europe, Australia, Asia, Americas). Assessments were conducted at baseline, 3, 6, and 12 months, with follow-ups at 18 and 24 months to evaluate clinical and functional outcomes. The study included 238 CHR individuals and 134 healthy controls (HC). At baseline, CHR and HC groups differed significantly in age, education, IQ, and vocational and relationship status. Cannabis and tobacco use did not significantly differ between groups, however CHR individuals had higher proportion of moderate to high risk of tobacco abuse. A substantial portion of the CHR sample met DSM criteria for anxiety (53.4%) and/or mood disorders (52.9%), with some prescribed antidepressants (38.7%), antipsychotics (13.9%), or benzodiazepines (16.4%). Over the follow-up period, 25 CHR individuals (10.5%) transitioned to psychosis. However, the CHR group as a whole showed improvements in functioning and attenuated psychotic symptoms. Similar to other recent multi-centre studies, the CHR cohort exhibits high comorbidity rates and relatively low psychosis transition rates. These findings highlight the clinical heterogeneity within CHR populations and suggest that outcomes extend beyond psychosis onset, reinforcing the need for broader prognostic models that consider functional and transdiagnostic outcomes.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"66"},"PeriodicalIF":3.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choice- and trial-history effects on causality perception in Schizophrenia Spectrum Disorder.","authors":"Kai Streiling, Rasmus Schülke, Benjamin Straube, Loes C J van Dam","doi":"10.1038/s41537-025-00614-0","DOIUrl":"https://doi.org/10.1038/s41537-025-00614-0","url":null,"abstract":"<p><p>Perceiving causality is a low-level, immediate cognitive process based on temporal and spatial cues relating to sensory events and could be viewed as a perceptual judgement. Perceptual judgements in general are affected by a choice- and trial history bias, however, it is not yet fully understood how such a bias integrates into the perception of causality. Here, we investigate judgements of perceptual causality in Schizophrenia Spectrum Disorder (SSD) as a perceptual decision process with systematic influences from past choices and experiences. We analysed previously collected data from a causality-judgement experiment using Michotte launching events and examined differences between patients with SSD (SSDs) and healthy control participants (HCs). We did this on several levels to shed light on known dysfunctions in the judgement of cause-effect relations in SSD, such as the jumping-to-conclusions bias. Using multiple Generalized Linear Mixed-Effects Models (GLMMs) revealed a significant direct influence of the choice-history for both participant groups. Trial-history (previous stimulus experiences) on the other hand appears to exert a more subtle influence on the current choice by modulating the effect of choice-history and current spatial and temporal properties. Regarding the stimulus of a given trial, SSDs relied more on spatial properties and less on temporal properties than HCs. Furthermore, an analysis of effects across time suggested an increasing reliance on previous choices for SSDs, and a decreasing effect for HCs. This hints towards a potentially maladaptive pattern which might contribute to biased causal attributions in SSD.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"65"},"PeriodicalIF":3.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric factors predict type 2 diabetes mellitus in US Veterans.","authors":"Lora Lee Pless, Chantele Mitchell-Miland, Yeon-Jung Seo, Charles B Bennett, Zachary Freyberg, Gretchen L Haas","doi":"10.1038/s41537-025-00616-y","DOIUrl":"https://doi.org/10.1038/s41537-025-00616-y","url":null,"abstract":"<p><p>Co-occurrence of type 2 diabetes mellitus (T2D) and serious mental illnesses (SMI) is prevalent yet underappreciated, and significantly contributes to increased morbidity and reduced lifespan. There is, therefore, a need to identify T2D risk factors to inform preventative approaches to the care of SMI-diagnosed patients. Our objective was to use predictive modeling methods to capture risk factors for T2D in a sample of 618,203 Veterans using data obtained from hospital electronic health records (EHR). This case-control study assessed VISN4 Veterans with and without T2D diagnoses and SMI diagnoses (schizophrenia, SZ; schizoaffective, SZA; bipolar disorder, BD; major depression, MDD; 2009-2019). Demographic variables and medications were obtained from the EHR. Following rigorous data quality control, 543,979 Veterans qualified for analysis (Age_mean[SD] = 65.9[17.6]years; body mass index(BMI)_mean[SD] = 28.6[6.0]kg/m²; N_T2D = 157,457[29%]; and N_male = 506,257[93.1%]). Veterans with co-occurring SMI + T2D included N_SZ = 2,087(36.5%), N_SZA = 1,345(36.3%), N_BD = 10,540(29.2%), and N_MDD = 20,510(30%) compared to 112,973(28.6%) non-SMI controls (NSC) with T2D. Factors that predicted T2D (R² = 34%) included age, sex, BMI, race/ethnicity, psychiatric diagnoses, and commonly prescribed psychiatric medications. Significant interactions were found between age (centered) and BMI on the odds of T2D (P < 0.001), as well as interaction between sex and BMI (P < 0.001), after adjusting for confounders. Veterans with SMI (SZ, MDD, SZA, and BD) had a higher likelihood of experiencing T2D, compared to the NSCs (OR_SZ = 1.30, 95% CI = 1.21-1.40; OR_MDD = 1.07, 95% CI = 1.05-1.10; OR_SZA = 1.26, 95% CI = 1.16-1.38; OR_BD = 1.05, 95% CI = 1.01-1.08). Finally, Veterans exposed to both selective serotonin reuptake inhibitor (SSRI) antidepressants and mood stabilizers had a 2.11 times increase in the odds of having T2D (95% CI = 2.06-2.16; P < 0.001) compared to Veterans not taking either medication. Four major psychiatric disorders (SZ, SZA, MDD, and BD) and several classes of medications used to treat them increased T2D risk. Our findings suggest that the measures assayed offer a potentially useful signal, that along with clinical, anthropometric, and biochemical measures can be used to ascertain metabolic risk. If confirmed with an independent sample, these findings could also inform medication choices made by prescribers.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"63"},"PeriodicalIF":3.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathways to prevention: the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program.","authors":"Barnaby Nelson, Martha E Shenton, Scott W Woods","doi":"10.1038/s41537-025-00605-1","DOIUrl":"https://doi.org/10.1038/s41537-025-00605-1","url":null,"abstract":"","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"62"},"PeriodicalIF":3.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}